dehydroepiandrosterone has been researched along with Response Evaluation Criteria in Solid Tumors in 1 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
Response Evaluation Criteria in Solid Tumors: An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pietri, E | 1 |
| Massa, I | 1 |
| Bravaccini, S | 1 |
| Ravaioli, S | 1 |
| Tumedei, MM | 1 |
| Petracci, E | 1 |
| Donati, C | 1 |
| Schirone, A | 1 |
| Piacentini, F | 1 |
| Gianni, L | 1 |
| Nicolini, M | 1 |
| Campadelli, E | 1 |
| Gennari, A | 1 |
| Saba, A | 1 |
| Campi, B | 1 |
| Valmorri, L | 1 |
| Andreis, D | 1 |
| Fabbri, F | 1 |
| Amadori, D | 1 |
| Rocca, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Non Randomized Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)[NCT02000375] | Phase 2 | 20 participants (Actual) | Interventional | 2013-03-31 | Terminated (stopped due to Due to slow recruitment and recent new published data) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for dehydroepiandrosterone and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aroma | 2019 |